
CFP Board Promotes Public Trust With Seven Actions
WASHINGTON--(BUSINESS WIRE)--Certified Financial Planner Board of Standards, Inc. (CFP Board), a nonprofit organization with more than 100,000 CFP ® professionals, today announced actions taken to uphold its ethical standards, imposing sanctions on seven individuals.
CFP Board is a professional body that has adopted a Code of Ethics and Standards of Conduct (Code and Standards) that benefits and protects the public and advances financial planning as a distinct and valuable profession. The Code and Standards requires that a CFP ® professional meet certain duties when providing professional services to a client, and to refrain from engaging in other misconduct that reflects adversely on their integrity or fitness as a certificant, on the CFP ® marks or on the profession. CFP® professionals make a commitment to CFP Board to abide by the Code and Standards, and their compliance reinforces the integrity of the CFP Board certification marks. CFP Board does not guarantee a CFP® professional's services, but it may sanction a CFP ® professional who fails to uphold their commitment. Information about how CFP Board addresses ethical issues involving CFP ® professionals and those pursuing initial CFP ® certification is available at CFP.net/enforcement.
At CFP.net/verify, the public can verify an individual's CFP ® certification status. CFP Board also provides links to other sources of information about CFP ® professionals that may be more recent or that may contain information that has not led to CFP Board discipline and does not appear on CFP Board's website, such as the Financial Industry Regulatory Authority's (FINRA's) BrokerCheck and the U.S. Securities and Exchange Commission's (SEC's) Investment Adviser Public Disclosure databases for individuals who are subject to FINRA or SEC oversight. CFP Board is not a federal, state or self-regulatory organization, and it does not sanction financial services firms.
The Public Sanctions on Seven Individuals
PUBLIC CENSURE
MARYLAND
Derrick P. Myers, CFP ® (Glen Burnie, Maryland): In March 2025, the Disciplinary and Ethics Commission (Commission) issued Mr. Myers a public censure for violating Standard E.8 of CFP Board's Code and Standards and Rule 6.5 of its Rules of Conduct, which require a CFP ® professional to refrain from engaging in conduct that reflects adversely on their integrity or fitness as a CFP ® professional, on the CFP ® marks or on the profession. The Commission found that Mr. Myers had failed to pay his firm's federal payroll taxes on time for the 2018-2020 tax years, resulting in a $147,901 federal tax lien against him. Mr. Myers still owed approximately $52,000 in federal taxes as of mid-September 2023, and his firm owed approximately $127,000 as of early February 2024. Both have complied with agreements they entered with the Internal Revenue Service (IRS) to pay the remaining balances in installments. In its order, the Commission also notes a $25,000 federal tax lien against Mr. Myers for the 2015 and 2016 tax years that the IRS later released. The Commission's order requires Mr. Myers to complete supplemental continuing education on tax planning, and for three years to certify to CFP Board every six months his progress toward resolving his and his firm's tax debts. The order was effective April 21, 2025. Read the order: Case History 45647.
OREGON
Robert Sevcik, CFP ® (Medford, Oregon): In March 2025, the Disciplinary and Ethics Commission (Commission) issued Mr. Sevcik a public censure. The Commission's order cites Mr. Sevcik's June 2021 termination from his firm over concerns that he had submitted transactions under production numbers that were inconsistent with an agreement he had with another representative. On October 11, 2022, Mr. Sevcik entered into a letter of Acceptance, Waiver and Consent (AWC) with the Financial Industry Regulatory Authority, Inc. (FINRA), which contains findings that from June 2014 through May 2021, he placed a total of 218 trades under improper codes, crediting him with higher commissions than he was entitled to under commission-splitting agreements he had with two retired representatives. By causing the firm to maintain inaccurate trade confirmations, Mr. Sevcik violated FINRA Rules 4511 and 2010. In its order, the Commission found that Mr. Sevcik violated Standard A.8.a of CFP Board's Code and Standards, which requires that a CFP ® professional comply with the laws, rules and regulations governing Professional Services; Rule 4.3 of the Rules of Conduct, which provides that a certificant shall be in compliance with applicable regulatory requirements governing professional services provided to the client; Standard D.2.a of the Code and Standards, which provides that a CFP ® professional will be subject to discipline by CFP Board for violating policies and procedures of their firm; and Standard E.3.j, which provides that a CFP ® professional must provide written notice to CFP Board within 30 calendar days after the CFP ® professional has been terminated for cause from employment for conduct involving allegations of dishonesty, unethical conduct or compliance failures. Read the order: Case History 43315.
SUSPENSION
CALIFORNIA
Bobby Koba (San Diego, California): In March 2025, counsel to the Disciplinary and Ethics Commission (Commission) issued an order suspending Mr. Koba's CFP Board certification and right to use the CFP Board certification marks. In December 2023, CFP Board enforcement counsel sent a notice of investigation to Mr. Koba concerning a customer complaint filed against him in September 2023, alleging unsuitable investments. Mr. Koba failed to acknowledge receipt of this notice or the second notice of investigation enforcement counsel delivered to him and was therefore in default under Article 4.1 of CFP Board's Procedural Rules. Based on a determination of the seriousness, scope and harmfulness of Mr. Koba's conduct, enforcement counsel filed a motion for administrative order of suspension, which counsel to the Commission granted on September 13, 2024. Mr. Koba is prohibited from applying for or obtaining CFP Board certification until he has been deemed eligible to apply for CFP ® certification in accordance with Article 4.6 of the Procedural Rules. The order was effective October 13, 2024. Read the order: Case History 46113.
TEMPORARY BAR
INDIANA
Carl L. Campbell (Columbus, Indiana): In April 2025, the Disciplinary and Ethics Commission (Commission) issued an order denying Mr. Campbell's petition for a determination that he is fit for CFP ® certification and barring him from applying for CFP ® certification for three years, retroactive to December 2024. Mr. Campbell was required to file his petition after he disclosed to CFP Board that he had filed for Chapter 7 bankruptcy in February 2023. In reaching its determination, the Commission noted that Mr. Campbell's bankruptcy filing occurred only two years ago. The bar is effective December 12, 2024, through December 12, 2027. Read the order: Case History 46774.
PERMANENT BAR
ARIZONA
Dan E. Droeg (Chandler, Arizona): In March 2025, counsel to the Disciplinary and Ethics Commission (Commission) issued an order permanently barring Mr. Droeg from CFP ® certification for failing to cooperate with CFP Board's investigation into his 2021 termination from his firm and subsequent regulatory actions taken against him. On February 11, 2022, Mr. Droeg entered into a Letter of Acceptance, Waiver and Consent (AWC) with FINRA barring him from associating with any FINRA member. In the AWC, Mr. Droeg consented to findings that, from 2015 to 2021, he used his authority as trustee of his client's charitable remainder trust to wrongfully convert more than $800,000 in trust assets to his own accounts. The state of Arizona brought its own action against Mr. Droeg and revoked his securities licenses. Over the course of its investigation, initiated in November 2021, CFP Board enforcement counsel allowed Mr. Droeg numerous opportunities to provide the information it had requested. Mr. Droeg failed to do so and, in November 2024, enforcement counsel issued him a notice of failure to cooperate under Article 1.3 of CFP Board's Procedural Rules. Mr. Droeg did not cure this failure and was therefore in default under Article 4.1. Based on a determination of the seriousness, scope and harmfulness of Mr. Droeg's conduct, enforcement counsel filed a motion seeking an administrative order that would permanently bar him from CFP ® certification, which counsel for the Commission granted on March 27, 2025. The order was effective April 28, 2025. Read the order: Case History 43681.
NEW YORK
Vincent J. Camarda (Amityville, New York): In April 2025, counsel to the Disciplinary and Ethics Commission (Commission) issued an order permanently barring Mr. Camarda from CFP ® certification for failing to cooperate with an investigation into several customer complaints against him. In one complaint made to CFP Board, clients alleged that Mr. Camarda misappropriated their life savings by investing them in an investment vehicle that he owned and then froze their accounts. The Commission had already imposed an interim suspension against Mr. Camarda in August 2022 after he was named in a complaint filed by the U.S. Securities and Exchange Commission (SEC), alleging securities laws violations relating to investments he had recommended and sold to clients. Mr. Camarda failed to acknowledge CFP Board enforcement counsel's January 2025 notice of investigation as required by Article 1.1 of CFP Board's Procedural Rules and was therefore in default under Article 4.1. Based on a determination of the seriousness, scope and harmfulness of Mr. Camarda's conduct, enforcement counsel filed a motion seeking an administrative order that would permanently bar him from CFP ® certification, which counsel for the Commission granted on April 4, 2025. The order was effective May 5, 2025. Read the order: Case History 46900.
TEXAS
David B. Test (Frisco, Texas): In March 2025, counsel to the Disciplinary and Ethics Commission (Commission) issued an administrative order permanently barring Mr. Test from future CFP ® certification. On June 22, 2023, CFP Board enforcement counsel filed a complaint against Mr. Test asserting that he had violated Standard A.8.a of the Code and Standards, which requires a CFP ® professional to comply with the laws, rules and regulations governing Professional Services, and Standard D.2.a. of the Code and Standards, which states that a CFP ® professional will be subject to discipline by CFP Board for violating policies and procedures of the CFP® professional's firm. The complaint alleges that Mr. Test was permitted to resign from his firm in lieu of termination for placing clients' initials on account transaction forms without the clients' knowledge or authorization. The complaint cites a January 19, 2023, Letter of Acceptance, Waiver and Consent (AWC) Mr. Test entered into with FINRA, which imposed on him a $5,000 fine and a two-month suspension from associating with any FINRA member for violating FINRA Rules 2010 and 4511. Mr. Test chose not to file an answer to CFP Board's complaint and was therefore in default under Article 4.1.e. of its Procedural Rules. Enforcement counsel filed a motion for an administrative order of permanent bar against Mr. Test based on a determination of the seriousness, scope and harmfulness of his conduct. Counsel to the Commission granted the motion on March 11, 2025. The order was effective on April 11, 2025. Read the order: Case History 43437.
# # #
ABOUT CFP BOARD
CFP Board is the professional body for personal financial planners in the U.S. CFP Board consists of two affiliated organizations focused on advancing the financial planning profession for the public's benefit. CFP Board of Standards sets and upholds standards for financial planning and administers the prestigious CERTIFIED FINANCIAL PLANNER ® certification — widely recognized by the public, advisors and firms as the standard for financial planners — so that the public has access to the benefits of competent and ethical financial planning. CFP ® certification is held by more than 100,000 people in the U.S. CFP Board Center for Financial Planning addresses diversity and workforce development challenges and conducts and publishes research that adds to the financial planning profession's body of knowledge.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@


Business Upturn
4 hours ago
- Business Upturn
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
9 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data